INGN Quote, Financials, Valuation and Earnings

Boston Scientific Corp. has a net margin of -5.73% compared to Inogen, Inc.'s net margin of 14.91%. Inogen, Inc.'s return on equity of -13.3% beat Boston Scientific Corp.'s return on equity of 12.46%.

Inogen, Inc. has a consensus price target of $13.00, signalling upside risk potential of 84.92%. On the other hand Boston Scientific Corp. has an analysts' consensus of $125.45 which suggests that it could grow by 28.48%. Given that Inogen, Inc. has higher upside potential than Boston Scientific Corp., analysts believe Inogen, Inc. is more attractive than Boston Scientific Corp..

Inogen, Inc. has a beta of 1.762, which suggesting that the stock is 76.168% more volatile than S&P 500. In comparison Boston Scientific Corp. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 33.029%.

Inogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen, Inc. pays -- of its earnings as a dividend. Boston Scientific Corp. pays out -- of its earnings as a dividend.

Inogen, Inc. quarterly revenues are $92.4M, which are smaller than Boston Scientific Corp. quarterly revenues of $5.1B. Inogen, Inc.'s net income of -$5.3M is lower than Boston Scientific Corp.'s net income of $755M. Notably, Inogen, Inc.'s price-to-earnings ratio is -- while Boston Scientific Corp.'s PE ratio is 52.23x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen, Inc. is 0.52x versus 7.53x for Boston Scientific Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Glaukos Corp. has a net margin of -5.73% compared to Inogen, Inc.'s net margin of -12.16%. Inogen, Inc.'s return on equity of -13.3% beat Glaukos Corp.'s return on equity of -11.73%.

Inogen, Inc. has a consensus price target of $13.00, signalling upside risk potential of 84.92%. On the other hand Glaukos Corp. has an analysts' consensus of $128.57 which suggests that it could grow by 13.86%. Given that Inogen, Inc. has higher upside potential than Glaukos Corp., analysts believe Inogen, Inc. is more attractive than Glaukos Corp..

Inogen, Inc. has a beta of 1.762, which suggesting that the stock is 76.168% more volatile than S&P 500. In comparison Glaukos Corp. has a beta of 0.668, suggesting its less volatile than the S&P 500 by 33.203%.

Inogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Glaukos Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen, Inc. pays -- of its earnings as a dividend. Glaukos Corp. pays out -- of its earnings as a dividend.

Inogen, Inc. quarterly revenues are $92.4M, which are smaller than Glaukos Corp. quarterly revenues of $133.5M. Inogen, Inc.'s net income of -$5.3M is higher than Glaukos Corp.'s net income of -$16.2M. Notably, Inogen, Inc.'s price-to-earnings ratio is -- while Glaukos Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen, Inc. is 0.52x versus 13.63x for Glaukos Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of -5.73% compared to Inogen, Inc.'s net margin of 28.31%. Inogen, Inc.'s return on equity of -13.3% beat Intuitive Surgical, Inc.'s return on equity of 16.38%.

Inogen, Inc. has a consensus price target of $13.00, signalling upside risk potential of 84.92%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $608.26 which suggests that it could grow by 3.76%. Given that Inogen, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Inogen, Inc. is more attractive than Intuitive Surgical, Inc..

Inogen, Inc. has a beta of 1.762, which suggesting that the stock is 76.168% more volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.669, suggesting its more volatile than the S&P 500 by 66.867%.

Inogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Inogen, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Inogen, Inc. quarterly revenues are $92.4M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.5B. Inogen, Inc.'s net income of -$5.3M is lower than Intuitive Surgical, Inc.'s net income of $709.2M. Notably, Inogen, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 77.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen, Inc. is 0.52x versus 22.18x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

West Pharmaceutical Services, Inc. has a net margin of -5.73% compared to Inogen, Inc.'s net margin of 17.41%. Inogen, Inc.'s return on equity of -13.3% beat West Pharmaceutical Services, Inc.'s return on equity of 17.44%.

Inogen, Inc. has a consensus price target of $13.00, signalling upside risk potential of 84.92%. On the other hand West Pharmaceutical Services, Inc. has an analysts' consensus of $345.71 which suggests that it could grow by 25.48%. Given that Inogen, Inc. has higher upside potential than West Pharmaceutical Services, Inc., analysts believe Inogen, Inc. is more attractive than West Pharmaceutical Services, Inc..

Inogen, Inc. has a beta of 1.762, which suggesting that the stock is 76.168% more volatile than S&P 500. In comparison West Pharmaceutical Services, Inc. has a beta of 1.167, suggesting its more volatile than the S&P 500 by 16.728%.

Inogen, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. West Pharmaceutical Services, Inc. offers a yield of 0.31% to investors and pays a quarterly dividend of $0.22 per share. Inogen, Inc. pays -- of its earnings as a dividend. West Pharmaceutical Services, Inc. pays out 12.27% of its earnings as a dividend. West Pharmaceutical Services, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Inogen, Inc. quarterly revenues are $92.4M, which are smaller than West Pharmaceutical Services, Inc. quarterly revenues of $804.3M. Inogen, Inc.'s net income of -$5.3M is lower than West Pharmaceutical Services, Inc.'s net income of $140M. Notably, Inogen, Inc.'s price-to-earnings ratio is -- while West Pharmaceutical Services, Inc.'s PE ratio is 40.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Inogen, Inc. is 0.52x versus 6.65x for West Pharmaceutical Services, Inc.. Usually stocks with elevated PS ratios are considered overvalued.